An important distinction to be made is the difference between a recurrent alteration within a patient population (for example, BRAF V600E in melanoma), and a gene acting as a driver within a particular tumour under a specific context (for example, germline variants, tissue type and therapeutic regimen). Here, BRAF is linked to neoplasm.